Methotrexate for the treatment of severe mucocutaneous lupus erythematosus.
We report three women with severe, chronic mucocutaneous lupus erythematosus who showed a significant improvement during oral methotrexate therapy; the improvement was sustained after the drug was discontinued. Their disease had previously been refractory to a wide range of conventional systemic immunosuppressive therapies. Other treatments were progressively withdrawn, and control was maintained, for a variable length of time, with methotrexate alone, or with a small dose of prednisolone.
Bottomley
W W
WW
Department of Dermatology, Leeds General Infirmary, U.K.
Goodfield
M
M
D000284:Administration, Oral; D000328:Adult; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D011239:Prednisolone; D008727:Methotrexate